Inclusion Criteria:

- Patients must have histologically confirmed invasive breast cancer.

- Patients must have either locally advanced (cT3-T4, N0-3 or cTx, T0-4, N2-N3) or
lymph node positive breast cancer

- Age >21 years. Because no dosing or adverse event data are currently available on
the use of docetaxel in patients <21 years of age, children are excluded from this
study but will be eligible for future pediatric phase 2 combination trials.

- Life expectancy of greater than 10 years.

- ECOG performance status <2 (Karnofsky >60%; see Appendix A).

- Patients must have normal organ and marrow function as defined below:

- leukocytes >3,000/mL

- absolute neutrophil count >1,500/mL

- platelets >100,000/mL

- total bilirubin within normal institutional limits

- AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal

- creatinine within normal institutional limits OR

- creatinine clearance >40 mL/min for patients if creatinine levels above
institutional normal

- The effects of docetaxel on the developing human fetus at the recommended therapeutic
dose are unknown. For this reason, women of child-bearing potential must agree to
use adequate contraception (hormonal or barrier method of birth control; abstinence)
prior to study entry and for the duration of study participation. Should a woman
become pregnant or suspect she is pregnant while participating in this study, she
should inform her treating physician immediately.

- Ability to understand and the willingness to sign a written informed consent
document.

Exclusion Criteria:

- HER2 positive breast cancer

- Metastatic breast cancer

- Patients who have had any chemotherapy or radiotherapy prior to entering the study.

- Patients receiving any other investigational agents.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to docetaxel, cyclophosphamide, lenograstim or filgrastim.

- History of pre-existing peripheral neuropathy

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Pregnant women are excluded from this study because chemotherapy in general including
docetaxel and cyclophosphamide used in this study are pregnancy class D agents with
the potential for teratogenic or abortifacient effects. Because there is an unknown
but potential risk for adverse events in nursing infants secondary to treatment of
the mother with chemotherapy, breastfeeding should be discontinued if the mother is
treated with chemotherapy. These potential risks may also apply to other agents used
in this study.

- Because patients with immune deficiency are at increased risk of lethal infections
when treated with marrow-suppressive therapy, HIV-positive patients receiving
combination anti-retroviral therapy are excluded from the study because of possible
pharmacokinetic interactions with chemotherapy or other agents administered during
the study. Appropriate studies will be undertaken in patients receiving combination
anti-retroviral therapy when indicated.

- Patients with prior malignancies are excluded except for basal cell carcinoma of the
skin and carcinoma in-situ of the cervix who have received curative treatment.

- Inclusion of Women and Minorities

- Both men and women of all races and ethnic groups are eligible for this trial.

- Protocol precautions and restrictions

- Patients who are pregnant or actively breast feeding are not eligible to participate
in this study as stated in 3.2.8. Female patients of child bearing potential will be
required to use reliable methods of contraception for the duration of the study and
until 4 weeks after the last dose of study treatment.